Released Mar 3, 2026, after the close
10-K filed Mar 3, 2026, 62 days after period end · 0001034842-26-000015
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$69.80M$69.80M derived+21.2% vs Q4 2024+0.5% vs Q3 2025
Net Income$268.07M$268.07M derived+1,769.2% vs Q4 2024+860.8% vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$23,170,000+39.1%
Operating Cash Flowderived$21,980,000+51.6%
Margins · derived
Operating margin33.2%+4.3 pt vs Q4 2024
Net margin384.0%+359.1 pt vs Q4 2024
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $69.80M | $57.60M | $35.79M | $51.28M |
| Net Income | $268.07M | $14.34M | $737.00K | $1.40M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR